Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis
{{output}}
Estrogen receptor alpha-positive (ER+) breast cancer remains a major clinical challenge due to the development of de novo and acquired resistance to endocrine therapy. (Z)-endoxifen (hereafter endoxifen), the most abundant active tamoxifen metabolite, has emer... ...
